The distribution pattern regarding occurrence of bacterial vaginosis is 18.8 % in celibate women, 25 % in pregnant women and 31.7 % in women who have ever been pregnant is considered as per the research findings of Center for Disease Control and Prevention. The risk factors associated with the disease etiology of bacterial vaginosis is pelvic inflammatory disease, preterm delivery of infants, urinary tract infection and sexually transmitted diseases (STD). The product pipeline in phase 3 for treatment of bacterial vaginosis are Metronidazole oral tablets 500mg | 1% SPL7013 Gel, GDC-229, Clindamycin 100mg and Ketoconazole 400mg and Association of metronidazole; nystatin and dexamethasone.

Oral route comprises of Metronidazole, Tinidazole, clindamycin and Secnidazole. The topical route includes Metronidazole, Clindamycin and normal pH restoration gels. The normal pH restoration gels is further sub segmented as Canesbalance and VivaGel®. Recent trends prevailing in the bacterial vaginosis drugs is understood by the inclusion of market size and forecast in the scope of the report.

The competitive landscape and attractive investment proposition gives clear idea that the first line treatment drugs employed for the treatment of bacterial vaginosis and the product pipeline of key manufacturers engaged in the bacterial vaginosis treatment industry. Collaborative partnership between the key players to promote recently approved drugs are mentioned in the company profiles considered for bacterial vaginosis drugs market. The major players in global bacterial vaginosis drugs market are Sanofi Aventis, Inc., Bayer AG, Mylan N.V., Novartis AG, Pfizer, Inc., Perrigo Company Plc, Sun Pharmaceutical Industries Ltd., Abbott Laboratories, Inc., Starpharma Holdings Limited and Symbiomix Therapeutics.

Bacterial vaginosis is the most common type of vaginal infection caused due to the pH imbalance in the vaginal environment which is triggered because of imbalance between good microflora Lactobacillus species with the bad microflora Gardnerella vaginalis. The clinical manifestation of bacterial vaginosis is asymptomatic in nature with the symptoms recurring with few days of earlier treatment with antibiotics. The treatment regimen is designed with drug formulations either oral or topical that are efficient in eliminating the colonization of Gardnerella vaginalis. Currently the antibiotics treatment is the preferred treatment regimen for bacterial vaginalis employing drugs such as metronidazole, clindamycin and Tinidazole. Broad spectrum antimicrobial activity e.g. secnidazole (Solosec) and immediate symptomatic relief makes antibiotic treatment the largest revenue grosser. Metronidazole is considered more beneficial than clindamycin for the treatment of bacterial vaginosis as it is safe during pregnancy and does not eliminate the colonization of good bacteria Lactobacillus species. Normal pH restoration gels e.g. Canesbalance (Bayer AG), VivaGel® (Starpharma Holdings)  will have an impressive growth in the near future as it address the key problem of microflora imbalance in vaginal environment and relatively has no side effects in comparison to the antibiotics. The prominent players in bacterial vaginosis drugs market are Abbott Laboratories, Inc., Bayer AG, Mylan N.V., Novartis AG, Pfizer, Inc., Perrigo Company Plc, Sun Pharmaceutical Industries Ltd., Sanofi Aventis, Starpharma Holdings Limited and Symbiomix Therapeutics.

Center for Disease Control and Prevention 2019 statistics has reported the prevalence of bacterial vaginosis in the North American women population to be around 84 % with no symptoms. The rising prevalence in the African American and Hispanic women has resulted the need for effective dosage regimen to give immediate relief. Domicile of key pharmaceutical industries engaged in the production and sale of antibiotics contributes to the dominance of North America in the bacterial vaginosis drugs market. European market is driven by rising prevalence of bacterial vaginosis due to increase in the lifetime number of sexual partners, recent influx of North African refugees with previous history of bacterial vaginosis has increased treatment burden to the European healthcare segment. Asia Pacific will enjoy a superlative growth in the bacterial vaginosis drugs market due to huge revenue generated by the generic antibiotic drugs market, poor socioeconomic conditions and lack of awareness regarding personal hygiene adds to the growth of Asia Pacific bacterial vaginosis drug market. Increasing disposable income and health awareness campaign regarding self hygiene by healthcare agencies such as World Health Organization and Red Cross will proliferate the bacterial vaginosis drugs market in Latin America and Middle East and Africa.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Bacterial Vaginosis Drugs market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Bacterial Vaginosis Drugs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Bacterial Vaginosis Drugs market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Bacterial Vaginosis Drugs market?
• Which is the largest regional market for Bacterial Vaginosis Drugs market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Bacterial Vaginosis Drugs market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Bacterial Vaginosis Drugs market worldwide?